Division of Infectious Diseases, Massachusetts General Hospital, Gray-Jackson 504, 55 Fruit Street, Boston, MA 02114, USA.
J Neurovirol. 2011 Jun;17(3):288-90. doi: 10.1007/s13365-011-0027-4. Epub 2011 Apr 13.
Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.
那他珠单抗（泰萨瑞，百健艾迪和艾尔建制药）是一种已被批准用于治疗多发性硬化症（MS）患者的单克隆抗体，也可用于治疗中度至重度克罗恩病。我们报告了首例患有 MS 病史，每月接受那他珠单抗治疗的患者发生单纯疱疹病毒 2 型（HSV-2）脑膜炎的病例。我们讨论了那他珠单抗的作用机制，并回顾了与这种药物相关的疱疹感染再激活的已知情况。这就引出了关于单纯疱疹病毒（HSV）和水痘带状疱疹病毒（VZV）预防的问题。
